Dropletbiosci
Melrose, US · Founded 2021 · 20 employees on LinkedIn · 2 known investors
Droplet Biosciences develops cancer diagnostics with a focus on liquid biopsy and precision oncology. The company works in the molecular diagnostics space for cancer detection and personalized medicine.
Also known as Droplet · Droplet Biosciences
Founders & leadership
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$13M disclosed across 2 rounds · 2021–2023
▶$7.6MraisedDec 2023 · 21 investors · BiotechnologyRule 506(b)
- Rachel ShaDirector
- Stanley LapidusDirector
- Theresa TribbleExecutive Officer, Director
- Ann DeWittDirector
- Jose ZevallosDirector
- Offering amount
- $14.1M
- Amount sold
- $7.6M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5.3MraisedMay 2021 · 30 investors · BiotechnologyRule 506(b)
- Stanley LapidusDirector
- Theresa TribbleExecutive Officer, Director
- Aadel ChaudhuriExecutive Officer, Director
- Ann DeWittDirector
- Jose ZevallosDirector
- Offering amount
- $5.3M
- Amount sold
- $5.3M
- Proceeds to insiders
- $337.5K
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Droplet Biosciences is a molecular diagnostics company developing a liquid biopsy approach based on lymphatic fluid rather than blood. The company has built a platform to harvest and profile patient lymph through the routine collection of surgical drain fluid, an approach it positions as making patient lymph accessible for research and diagnosis for the first time in routine practice. Its lead offering is described as LymphDetect.
The company frames the scientific rationale around the lymphatic system's long-recognized role in metastasis: lymph fluid regulates immune responses to pathogens and cancer and is presented as a concentrated, proximal source of lymphocytes, proteins and other biomarkers reflecting the tumor microenvironment. Because drain fluid is available immediately after surgery and is collected near the tumor site, Droplet positions its assay for local assessment of recurrence risk and for informing adjuvant treatment decisions in the post-surgical setting. Beyond the diagnostic itself, the company describes accumulating a lymph dataset intended to support insights into areas such as patient selection and treatment response.
Traction
The company promotes LymphDetect and a collaboration with NVIDIA.
Latest developments
The company has publicized a collaboration with NVIDIA and continues to promote its LymphDetect assay.
▸Full profile — market position, technology, go-to-market, geography
Market position
Droplet Biosciences positions itself in the liquid biopsy and precision oncology field, differentiating from blood-based testing by using lymphatic fluid collected from surgical drains.
The company's stated differentiation rests on three attributes of lymph-based sampling: novelty, in that concentrated lymphatic fluid offers a window into the tumor microenvironment; proximity, in that samples are taken near the tumor site for local recurrence risk assessment; and timing, in that drain fluid is available immediately after surgery to support adjuvant decision-making. The company also notes that routine access to patient lymph has historically not been feasible.
Technology
Droplet's platform harvests and profiles lymphatic fluid obtained through routine surgical drain fluid collection, an approach the company presents as an alternative to blood-based liquid biopsy. The company states that concentration of lymphatic fluid provides an enhanced window into the tumor microenvironment, that proximity to the tumor site yields superior local assessment of recurrence risk, and that availability immediately after surgery enables adjuvant decision-making. Alongside the assay, the company is building a lymph dataset intended to generate insights into patient selection and treatment response.
Go-to-market
Surgical and oncology care settings where patients have undergone tumor resection and surgical drains are placed, with results intended to inform clinicians making post-surgical adjuvant treatment decisions.
Geography
Headquartered in Melrose, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 4
by search overlap
Companies competing with Dropletbiosci for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsDroplet Biosciences announced a collaboration with NVIDIA, highlighted via a press release linked from its website.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Dropletbioscidropletbiosci.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Dropletbiosci do?
- Droplet Biosciences is a liquid biopsy company profiling patient lymph from surgical drain fluid to assess cancer recurrence risk.
- Who are Dropletbiosci's investors?
- Dropletbiosci's investors include Safar Partners, The Engine Ventures.
- How much funding has Dropletbiosci raised?
- Dropletbiosci has disclosed $13M raised across 2 rounds.
- Where is Dropletbiosci headquartered?
- Dropletbiosci is headquartered in Melrose, US.